Lilly (LLY) Says New Data Showcasing its Growing Commitment in Rheumatology to be Featured at ACR/ARHP
Tweet Send to a Friend
Eli Lilly and Company (NYSE: LLY) announced that it will present new data for Taltz® (ixekizumab) and Olumiant® (baricitinib) at ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
